This is the short take from Practice Update this morning. Link to the abstract is included. The three practice changing points included are worth noting. Makes me happy. (Came off of wonderful 3 day backpack around Grand Teton yesterday. Today, back into it in Yellowstone. Pic is of the Grand Teton. Stood on top back in 2006, one year before PC.)
practiceupdate.com/c/139708...
TAKE-HOME MESSAGE
In this review, the authors outline the evidence to date from clinical trials assessing the utility of radiotherapy in patients with oligometastatic prostate cancer.
Primary prostate radiation in the de novo metastatic setting prolongs biochemical progression–free survival (BPFS) and may provide a survival benefit in patients with less than five bone metastases.
Metastasis-directed therapy in the form of stereotactic ablative body radiotherapy (SABR) may provide benefits beyond local control in both patients with hormone-sensitive and hormone-resistant prostate cancer, including longer BPFS and radiologic PFS.Radiotherapy, particularly SABR, should be considered in patients with oligometastatic prostate cancer. Highly-sensitive imaging modalities, such as PSMA PET, are essential to identify patients most likely to benefit from radiotherapy.